Ségolène Martin, CEO and co-founder of Kantify
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Ségolène Martin, CEO and co-founder of Kantify
-
Narrated by:
-
By:
About this listen
Artificial Intelligence (AI) technologies are revolutionizing almost every field. Drug discovery - the process of identifying druggable targets and potential therapeutic compounds - is a long, costly, and often laborious process wherein researchers may sift through thousands of therapeutic candidates for a target looking for a hit.
After many decades of experimentation, millions of data points on targets and therapeutic compounds exist for all kinds of disease indications. This is far too much information for even a top team of humans to interpret, but can artificial intelligence algorithms make sense of it all to improve the drug discovery process?
In this episode of BioInnovator Spotlight, we speak with Ségolène Martin, CEO and co-founder of Kantify, a company using AI technology to improve drug discovery in a variety of fields such as oncology and neuromuscular disorders.